Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors

C Dickson, B Spencer-Dene, C Dillon, V Fantl, C Dickson, B Spencer-Dene, C Dillon, V Fantl

Abstract

The fibroblast growth factors [Fgfs (murine), FGFs (human)] constitute a large family of ligands that signal through a class of cell-surface tyrosine kinase receptors. Fgf signalling has been associated in vitro with cellular differentiation as well as mitogenic and motogenic responses. In vivo, Fgfs are critical for animal development, and some have potent angiogenic properties. Several Fgfs have been identified as oncogenes in murine mammary cancer, where their deregulation is associated with proviral insertions of the mouse mammary tumour virus (MMTV). Thus, in some mammary tumours of MMTV-infected mouse strains, integration of viral genomic DNA into the somatic DNA of mammary epithelial cells was found to have caused the inappropriate expression of members of this family of growth factors. Although examination of human breast cancers has shown an altered expression of FGFs or of their receptors in some tumours, their role in the causation of breast disease is unclear and remains controversial.

Figures

Figure 1
Figure 1
Fgf receptor structure and Fgf signalling. Structural domains of an Fgf receptor are shown on the right of the panel. Fgf signal transduction is initiated upon binding the Fgf ligand in conjunction with heparan sulphate to form a ternary complex. The result is autophosphorylation and activation of the tyrosine kinase, which facilitates second messenger signalling through phosphotyrosine-dependent and -independent interactions with the cytoplasmic portion of the receptor.
Figure 2
Figure 2
Proto-oncogene activation by insertional mutagenesis of MMTV. (a) Insertion of viral genomic DNA into somatic cellular DNA in close proximity of a silent oncogene. (b) Inserted proviral DNA induces the transcription of the oncogene.

References

    1. Basilico C, Moscatelli D. The FGF family of growth-factors and oncogenes. Adv Cancer Res. 1992;59:115–165.
    1. Johnson D, Williams L. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1–41.
    1. McKeehan WL, Wang F, Kan M. The heparan-sulfate fibroblast growth-factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998;59:135–176.
    1. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Frontiers Biosci. 1999;4:165–177.
    1. Bugler B, Amalric F, Prats H. Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol. 1991;11:573–577.
    1. Renko M, Quarto N, Morimoto T, Rifkin D. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol. 1990;144:108–114.
    1. LaVallee TM, Tarantini F, Gamble S, et al. Synaptotagmin-1 is required for fibroblast growth-factor-1 release. J Biol Chem. 1998;273:22217–22223.
    1. Florkiewicz R, Anchin J, Baird A. The inhibition of fibroblast growth factor-2 export by carenolides implies a novel function for the catalytic subunit of Na+,K+-ATPase. J Biol Chem. 1998;273:544–551.
    1. Tarantini F, LaVallee T, Jackson A, et al. The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to heat shock. J Biol Chem. 1998;273:22209–22216.
    1. Zhan X, Hu XG, Friedman S, Maclag T. Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH3T3 cells. Biochem Biophys Res Commun. 1992;188:982–991.
    1. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 1991;67:229–231.
    1. Ornitz DM, Xu JS, Colvin JS, et al. Receptor specificity of the fibroblast growth-factor family. J Biol Chem. 1996;271:15292–15297.
    1. Peters K, Werner S, Chen G, Williams L. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development. 1992;114:233–243.
    1. Orr-Urtreger A, Bedford M, Burakova T, et al. Developmental localization of the splicing alternatives of fibroblast growth-factor receptor-2 (FGFR2). Dev Biol. 1993;158:475–486. doi: 10.1006/dbio.1993.1205.
    1. Peters K, Ornitz D, Werner S, Williams L. Unique expression pattern of the fgf receptor-3 gene during mouse organogenesis. Dev Biol. 1993;155:423–430. doi: 10.1006/dbio.1993.1040.
    1. Partanen J, Armstrong E, Makela TP, et al. A novel endothelial-cell surface-receptor tyrosine kinase with extracellular epidermal growth-factor homology domains. Mol Cell Biol. 1992;12:1698–1707.
    1. Stark K, McMahon J, McMahon A. FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse. Development. 1991;113:641–651.
    1. Plontnikov A, Schlessinger J, Hubbard S, Mohammadi M. Structural basis of fgf receptor dimerization and activation. Cell. 1999;98:641–650.
    1. Werner S, Smola H, Liao X, et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science. 1994;266:819–822.
    1. Yamaguchi TP, Rossant J. Fibroblast growth-factors in mammalian development. Curr Opin Genet Dev. 1995;5:485–491.
    1. Martin G. The roles of FGFs in the early development of vertebrate limbs. Genes Dev. 1998;12:1571–1586.
    1. DeVore DL, Horvitz HR, Stern MJ. An FGF receptor signaling pathway is required for the normal-cell migrations of these sex myoblasts in C-elegans hermaphrodites. Cell. 1995;83:611–620.
    1. Glazer L, Shilo B-Z. The Drosophila FGF-R homolog is expressed in the embryonic tracheal system and appears to be required for directed tracheal cell extension. Genes Dev. 1991;5:697–705.
    1. DeMoerlooze L, Dickson C. Skeletal disorders associated with fibroblast growth-factor receptor mutations. Curr Opin Genet Dev. 1997;7:378–385.
    1. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99–109.
    1. Nusse R, Brown A, Papkoff J, et al. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell. 1991;64:231–232.
    1. Peters G, Brookes S, Smith R, Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell. 1983;33:369–377.
    1. Peters G, Lee A, Dickson C. Concerted activation of two potential proto-oncogenes in carcinomas induced by mouse mammary tumour virus. Nature. 1986;320:628–631.
    1. Stamp G, Fantl V, Poulsom R, et al. Nonuniform expression of a mouse mammary tumor virus-driven int-2/Fgf-3 transgene in pregnancy-responsive breast tumors. Cell Growth Differ. 1992;3:929–938.
    1. Ornitz D, Cardiff R, Kuo A, Leder P. Int-2, an autocrine and/or ultra-short-range effector in transgenic mammary tissue transplants. J Natl Cancer Inst. 1992;84:887–892.
    1. Muller W, Lee F, Dickson C, et al. The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J. 1990;9:907–913.
    1. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988;55:619–625.
    1. Kwan H, Pecenka V, Tsukamoto A, et al. Transgenes expressing the wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol. 1992;12:147–154.
    1. Shackleford GM, MacArthur CA, Kwan HC, Varmus HE. Mouse mammary-tumor virus-infection accelerates mammary carcinogenesis in wnt-1 transgenic mice by insertional activation of int-2/fgf-3 and hst/fgf-4. Proc Natl Acad Sci USA. 1993;90:740–744.
    1. MacArthur CA, Shankar DB, Shackleford GM. FGF-8, activated by proviral insertion, cooperates with the wnt-1 transgene in murine mammary tumorigenesis. J Virol. 1995;69:2501–2507.
    1. Lammie GA, Peters G. Chromosome 11q13 abnormalities in human cancer. Cancer Cells. 1991;3:413–420.
    1. Penault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast-cancer. Int J Cancer. 1995;61:170–176.
    1. Relf M, LeJeune S, Scott P, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963–969.
    1. Smith K, Fox SB, Whitehouse R, et al. Upregulation of basic fibrob last growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999;10:707–713.
    1. Colomer R, Aparicio J, Monero S, et al. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor pronosis in human breast carcinoma. Br J Cancer. 1997;76:1215–1220.
    1. Anandappa SY, Winstanley JHR, Leinster S, et al. Comparative expression of fibroblast growth-factor messenger-RNAs in benign and malignant breast disease. Br J Cancer. 1994;69:772–776.
    1. Luqmani Y, Graham M, Coombes R. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer. 1992;66:271–280.
    1. Yiangou C, Gomm JJ, Coope RC, et al. Fibroblast growth factor-2 in breast cancer occurrence and prognostic significance. Br J Cancer. 1997;75:28–33.
    1. Linder C, Bystom P, Engel G, et al. Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma. Br J Cancer. 1998;77:941–945.
    1. Smith J, Yelland A, Baillie R, Coombes RC. Acidic and basic fibroblast growth-factors in human breast-tissue. Eur J Cancer. 1994;30A:496–503.
    1. Bansal GS, Yiangou C, Coope RC, et al. Expression of fibroblast growth-factor-1 is lower in breast-cancer than in the normal human breast. Br J Cancer. 1995;72:1420–1426.
    1. Coope RC, Browne PJ, Yiangou C, et al. The location of acidic fibroblast growth-factor in the breast is dependent on the activity of proteases present in breast-cancer tissue. Br J Cancer. 1997;75:1621–1630.
    1. Marsh SK, Bansal GS, Zammit C, et al. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene. 1999;18:1053–1060. doi: 10.1038/sj/onc/1202392.
    1. Tanaka A, Furuya A, Yamasaki M, et al. High-frequency of fibroblast-growth-factor (FGF)-8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal-antibody against FGF-8. Cancer Res. 1998;58:2053–2056.
    1. Theillet C, Adelaide J, Louason G, et al. FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer. 1993;7:219–226.
    1. Adnane J, Gaudray P, Dionne C, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 1991;6:659–663.
    1. Blanckaert VD, Hebbar M, Louchez MM, et al. Basic fibroblast-growth-factor receptors and their prognostic value in human breast-cancer. Clin Cancer Res. 1998;4:2939–2947.
    1. Cappellen D, Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinoma. Nature Genet. 1999;23:18–20.
    1. Neilson KM, Friesel R. Ligand-independent activation of fibroblast growth-factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J Biol Chem. 1996;271:25049–25057.
    1. Naski MC, Wang Q, Xu JS, Ornitz DM. Graded activation of fibroblast growth-factor receptor3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 1996;13:233–237.
    1. Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth-factor receptor-3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 1996;15:520–527.
    1. Jackson D, Bresnick J, Rosewell I, et al. Fibroblast growth-factor receptor signaling has a role in lobuloalveolar development of the mammary-gland. J Cell Sci. 1997;110:1261–1268.
    1. Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P. Insertional mutagenesis identifies a member of the wnt gene family as a candidate oncogene in the mammary epithelium of int-2/FGF-3 transgenic mice. Proc Natl Acad Sci USA. 1995;92:2268–2272.
    1. Gallahan D, Kozak C, Callahan R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J Virol. 1987;61:218–220.
    1. Peters G, Brookes S, Smith R, Placzek M, Dickson C. The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and activated by proviral insertion in some virally induced mammary tumors. Proc Natl Acad Sci USA. 1989;86:5678–5682.
    1. Roelink H, Wagenaar E, Lopes de Silva S, Nusse R. Wnt-3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int-1/wnt-1 and is normally expressed in mouse embryos and adult brain. Proc Natl Acad Sci USA. 1990;87:4519–4523.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe